Author/Editor		Muzlovič, Igor; Jereb, Matjaž; Beović, Bojana; Tomažič, Janez; Pikelj, Franjo
Title		Primerjava učinkovitosti cefpiramida (tamicin) in cefotaksima pri zdravljenju hudih bolnišničnih in izvenbolnišničnih okužb
Translated title		Treatment of serious hospital and community acquired infection: cefpiramide (tamicin) versus cefotaxime
Type		članek
Source		Zdrav Vestn
Vol. and No.		Letnik 66, št. 3
Publication year		1997
Volume		str. 123-6
Language		slo
Abstract		Backgraund. The activity of cefpiramide is usually compared to activity of cefoperazone against P. aeruginosa. It has about the same activity as cefotaxim and ceftriaxone against gram negative bacteria. In prospective randomised clinical trial the activity of cefpiramide (Tamicin/R) was compared to that of cefotoxim in patients who suffered from serious nosocomial and community acquired infections. Methods. Thirty-one patients with pneumonia, sepsis or urinary tract infection were randomly assigned to one of the two groups. Patients in the first group received intravenous cefpiramide and patients in the second group received intravenous cefotaxim. There was no difference between groups according to demographic characteristics. Results. Cefpiramide was clinically successful in 85.7% and 78.5% of cases showed eradication of causative pathogen. Cefotaxim was clinically successful in 76.4% and eradication rate was 85.7%. The most frequent isolated bacteria in both groups were E. coli, K. pneumoniae and P. aeruginosa. E. cloacae was more frequently in cefpiramide group and S. aureus in cefotaxim group. There were no differences in the both groups according to colonization, superinfection or side effects. Conclusions. Cefpiramide and cefotaxim were equally effective and safe in patients with serious hospital and community acquired infections. Treatment with these drugs is recommended in infections that are not multiresistant in origin.
Summary		Izhodišča. Delovanje cefpiramida na P. aeruginosa je primerljivo delovanju cefoperazona. Ima podoben učinek kot cefotaksim ter deftriakson na gram negativne bakterije. V prospektivni randomizirani klinični raziskavi smo primerjali učinek cefpiramida (Tamicin/R) z učinkom cefotaksima pri zdravljenju hudih bolnišničnih in izvenbolnišničnih okužb. Metode. Enaintrideset bolnikov, ki so zboleli za pljučnico, sepso ali vnetjem sečil, je bilo razdeljenih v dve skupini. Bolniki v prvi skupini so prejemali cefpiramid, bolniki v drugi skupini pa cefotaksim v intravenski obliki. Med obema skupinama ni bilo demografskih razlik. Rezultati. Cefpiramid je bil klinično učinkovit v 85,7% in bakteriološko v 78,5%, medtem ko je bil cefotaksim uspešen klinično v 76,4% in bakteriološko v 85,7%. Najpogosteje izolirani povzročitelji v obeh skupinah so bili E. coli, K. pneumoniae, P. aeruginosa. E. cloacae je bil pogostejši v skupini, ki je prejemala cefpiramid, in S. aureus v skupini, ki je prejemala cefotaksim. Kolonizacije, superinfekcije in stranski učinki so se pojavljali enakomerno v obeh skupinah. Zaključki. Zdravljenje hudih bolnišničnih in izvenbolnišničnih okužb s cefpiramidom in cefotaksimom je bilo enakovredno in varno. Primerno je takrat, ko okužbo ne povzročajo bakterije, odporne na več antibiotikov.
Descriptors		CROSS INFECTION COMMUNITY-ACQUIRED INFECTIONS PNEUMONIA SEPSIS PYELONEPHRITIS ADULT MIDDLE AGE AGED PROSPECTIVE STUDIES CEFOTAXIME CEPHALOSPORINS